| pubmed-article:20446121 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20446121 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
| pubmed-article:20446121 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:20446121 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20446121 | pubmed:dateCreated | 2010-6-7 | lld:pubmed |
| pubmed-article:20446121 | pubmed:abstractText | Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL. | lld:pubmed |
| pubmed-article:20446121 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20446121 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20446121 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20446121 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:20446121 | pubmed:issn | 1558-822X | lld:pubmed |
| pubmed-article:20446121 | pubmed:author | pubmed-author:BartlettNancy... | lld:pubmed |
| pubmed-article:20446121 | pubmed:author | pubmed-author:FoyilKelley... | lld:pubmed |
| pubmed-article:20446121 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20446121 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:20446121 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20446121 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20446121 | pubmed:pagination | 140-7 | lld:pubmed |
| pubmed-article:20446121 | pubmed:dateRevised | 2010-11-26 | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:meshHeading | pubmed-meshheading:20446121... | lld:pubmed |
| pubmed-article:20446121 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20446121 | pubmed:articleTitle | Anti-CD30 Antibodies for Hodgkin lymphoma. | lld:pubmed |
| pubmed-article:20446121 | pubmed:affiliation | Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid, Box 8056, St. Louis, MO 63110, USA. | lld:pubmed |
| pubmed-article:20446121 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20446121 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20446121 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20446121 | lld:pubmed |
